{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,7,8]],"date-time":"2024-07-08T07:14:25Z","timestamp":1720422865207},"reference-count":29,"publisher":"Wiley","issue":"2","license":[{"start":{"date-parts":[[2011,10,20]],"date-time":"2011-10-20T00:00:00Z","timestamp":1319068800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Intl Journal of Cancer"],"published-print":{"date-parts":[[2012,7,15]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Women with a significant family history of breast cancer are generally offered early surveillance by mammography and often clinical breast examination (CBE). The evidence base for surveillance has been questioned. We reviewed its effectiveness in terms of tumour size, lymph node status and survival in 7,475 women seen over a 22\u2010year period in the Manchester Family History Clinic. We diagnosed 139 invasive and 26 <jats:italic>in situ<\/jats:italic> breast cancers. Seventy\u2010six percent of the invasive cancers were screen detected, 65% node negative and 71% &lt;2cm in diameter at diagnosis. Twenty\u2010one tumours were <jats:italic>BRCA1<\/jats:italic> positive and were significantly more likely to be grade 3, ER\/PR negative (<jats:italic>p<\/jats:italic> &lt; 0.0001) and have a poorer survival. CBE contributed to 30% of cancer diagnoses and was responsible for discovery of nine mammographically occult tumours. The cost per quality life year was estimated at \u00a313,080 for tumours detected by CBE and not by mammography. We conclude that screening by annual mammography and CBE between age 35\u201350 years and 18 monthly from 50 to 60 years may diagnose breast cancer in a less advanced state in terms of size and node status compared with symptomatic cancers and, apart from <jats:italic>BRCA1<\/jats:italic> carriers, is likely to contribute to improved long\u2010term outcome compared with no surveillance.<\/jats:p>","DOI":"10.1002\/ijc.26394","type":"journal-article","created":{"date-parts":[[2011,8,31]],"date-time":"2011-08-31T22:18:16Z","timestamp":1314829096000},"page":"417-425","source":"Crossref","is-referenced-by-count":19,"title":["Surveillance of women at increased risk of breast cancer using mammography and clinical breast examination: Further evidence of benefit"],"prefix":"10.1002","volume":"131","author":[{"given":"Andrew","family":"Maurice","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"D. Gareth","family":"Evans","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jenny","family":"Affen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rosemary","family":"Greenhalgh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stephen W.","family":"Duffy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anthony","family":"Howell","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2011,10,20]]},"reference":[{"key":"e_1_2_7_2_2","unstructured":"Cancer Research UK Statistics. Available at:http:\/\/info.cancerresearchuk.org\/cancerstats\/index.htm. Accessed 1st June 2011."},{"key":"e_1_2_7_3_2","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1093\/oxfordjournals.aje.a115616","article-title":"Family history, age, and risk of fatal breast cancer","volume":"131","author":"Calle EE","year":"1990","journal-title":"Am J Epidemiol"},{"key":"e_1_2_7_4_2","doi-asserted-by":"publisher","DOI":"10.1097\/01.GIM.0000151155.36470.FF"},{"key":"e_1_2_7_5_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMsa0708739"},{"key":"e_1_2_7_6_2","first-page":"782","article-title":"The pathology of familial breast cancer: histological features of cancers in families not attributable to mutations in BRCA1 or BRCA2","volume":"6","author":"Lakhani SR","year":"2000","journal-title":"Clin Cancer Res"},{"key":"e_1_2_7_7_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(10)70263-1"},{"key":"e_1_2_7_8_2","first-page":"4053","article-title":"Familial invasive breast cancers: worse outcome related to BRCA1 mutations","volume":"24","author":"Stoppa\u2010Lyonnet D","year":"2000","journal-title":"Clin Oncol"},{"key":"e_1_2_7_9_2","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.22789"},{"key":"e_1_2_7_10_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa070608"},{"key":"e_1_2_7_11_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0959-8049(00)00098-8"},{"key":"e_1_2_7_12_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0959-8049(98)00005-7"},{"key":"e_1_2_7_13_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2006.01.055"},{"key":"e_1_2_7_14_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2006.12.009"},{"key":"e_1_2_7_15_2","doi-asserted-by":"publisher","DOI":"10.1136\/jmg.37.3.203"},{"key":"e_1_2_7_16_2","unstructured":"Familial breast cancer: the classification and care of women at risk of familial breast cancer in primary secondary and tertiary care. National Institute for Health and Clinical Excellence. Clinical guidelines CG41. Issued: October 2006 updated from original comprehensive guidance CG14 June 2004. Available at:www.nice.org.uk."},{"key":"e_1_2_7_17_2","doi-asserted-by":"publisher","DOI":"10.1136\/jmg.40.11.807"},{"key":"e_1_2_7_18_2","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/djq088"},{"key":"e_1_2_7_19_2","first-page":"160","article-title":"Physical examination: evaluation of its role as a single screening modality in the Canadian National Breast Screening Study","volume":"63","author":"Baines CJ","year":"1989","journal-title":"Cancer"},{"key":"e_1_2_7_20_2","doi-asserted-by":"publisher","DOI":"10.1007\/s10549-008-0100-8"},{"key":"e_1_2_7_21_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(05)66481-1"},{"key":"e_1_2_7_22_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.292.11.1317"},{"key":"e_1_2_7_23_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.04.0345"},{"key":"e_1_2_7_24_2","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-07-0146"},{"key":"e_1_2_7_25_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(96)10109-4"},{"key":"e_1_2_7_26_2","doi-asserted-by":"publisher","DOI":"10.3322\/canjclin.54.6.345"},{"key":"e_1_2_7_27_2","doi-asserted-by":"publisher","DOI":"10.1258\/096914103321610761"},{"key":"e_1_2_7_28_2","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.10695"},{"key":"e_1_2_7_29_2","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/djp241"},{"key":"e_1_2_7_30_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0959-8049(01)00207-6"}],"container-title":["International Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fijc.26394","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/ijc.26394","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,16]],"date-time":"2023-10-16T20:27:17Z","timestamp":1697488037000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/ijc.26394"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,10,20]]},"references-count":29,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2012,7,15]]}},"alternative-id":["10.1002\/ijc.26394"],"URL":"https:\/\/doi.org\/10.1002\/ijc.26394","archive":["Portico"],"relation":{},"ISSN":["0020-7136","1097-0215"],"issn-type":[{"value":"0020-7136","type":"print"},{"value":"1097-0215","type":"electronic"}],"subject":[],"published":{"date-parts":[[2011,10,20]]}}}